TG Therapeutics, Inc. (TGTX)
55.37
+2.03
(+3.81%)
USD |
NASDAQ |
Oct 09, 16:00
55.00
-0.37
(-0.67%)
Pre-Market: 20:00
TG Therapeutics 30-Day Average Daily Volume : 1.816M for Oct. 9, 2026
30-Day Average Daily Volume Chart
Historical 30-Day Average Daily Volume Data
| Date | Value |
|---|---|
| October 09, 2026 | 1.816M |
| October 08, 2026 | 1.802M |
| October 07, 2026 | 1.777M |
| October 06, 2026 | 1.793M |
| October 05, 2026 | 1.807M |
| October 02, 2026 | 1.941M |
| October 01, 2026 | 1.967M |
| September 30, 2026 | 1.939M |
| September 29, 2026 | 1.916M |
| September 28, 2026 | 1.897M |
| September 25, 2026 | 1.885M |
| September 24, 2026 | 1.934M |
| September 23, 2026 | 1.963M |
| September 22, 2026 | 1.942M |
| September 21, 2026 | 1.937M |
| September 18, 2026 | 1.924M |
| September 17, 2026 | 1.799M |
| September 16, 2026 | 1.845M |
| September 15, 2026 | 1.862M |
| September 14, 2026 | 2.017M |
| September 11, 2026 | 2.055M |
| September 10, 2026 | 2.104M |
| September 09, 2026 | 2.156M |
| September 08, 2026 | 2.186M |
| September 04, 2026 | 2.206M |
| Date | Value |
|---|---|
| September 03, 2026 | 2.221M |
| September 02, 2026 | 2.267M |
| September 01, 2026 | 2.233M |
| August 31, 2026 | 2.176M |
| August 28, 2026 | 2.156M |
| August 27, 2026 | 2.236M |
| August 26, 2026 | 2.268M |
| August 25, 2026 | 2.290M |
| August 24, 2026 | 2.291M |
| August 21, 2026 | 2.261M |
| August 20, 2026 | 2.117M |
| August 19, 2026 | 2.087M |
| August 18, 2026 | 2.106M |
| August 17, 2026 | 2.137M |
| August 14, 2026 | 2.191M |
| August 13, 2026 | 2.258M |
| August 12, 2026 | 2.233M |
| August 11, 2026 | 2.251M |
| August 10, 2026 | 2.273M |
| August 07, 2026 | 2.438M |
| August 06, 2026 | 2.465M |
| August 05, 2026 | 2.509M |
| August 04, 2026 | 2.519M |
| August 03, 2026 | 2.556M |
| July 31, 2026 | 2.581M |
30-Day Average Daily Volume Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
30-Day Average Daily Volume Benchmarks
| Krystal Biotech, Inc. | 280311.5 |
| Vertex Pharmaceuticals, Inc. | 1.034M |
| SELLAS Life Sciences Group, Inc. | 6.050M |
| Travere Therapeutics, Inc. | 1.702M |
| Alnylam Pharmaceuticals, Inc. | 1.492M |